Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$68,457 Mln
P/E Ratio
28.06
P/B Ratio
14.24
Industry P/E
--
Debt to Equity
1.41
ROE
0.51 %
ROCE
21.37 %
Div. Yield
1.31 %
Book Value
10.49
EPS
5.47
CFO
$15,538.00 Mln
EBITDA
$21,920.00 Mln
Net Profit
$13,668.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Zoetis Inc. Class A (ZTS)
| -5.52 | -6.72 | -11.04 | -2.83 | -4.81 | 3.85 | 12.64 |
|
BSE Sensex
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P 100
| -7.92 | -4.31 | -10.18 | 11.53 | 11.23 | 15.43 | 11.17 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Zoetis Inc. Class A (ZTS)
| -17.32 | 34.68 | -39.95 | 48.26 | 25.76 | 55.71 | 19.33 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 189.23 | 329,136.41 | 78.18 | 62.52 | |
| 869.36 | 794,307.13 | 75.67 | 84.41 | |
| 155.13 | 371,930.30 | 17.19 | 29.42 | |
| 83.24 | 208,206.09 | 12.03 | 40.81 |
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and... internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey. Read more
CEO & Director
Ms. Kristin C. Peck
CEO & Director
Ms. Kristin C. Peck
Headquarters
Parsippany, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Zoetis Inc Class A (ZTS) stood at $ 14,237 Mln as on 31-Dec-24
The share price of Zoetis Inc Class A (ZTS) is $153.95 (NYSE) as of 28-Apr-2025 11:37 EDT. Zoetis Inc Class A (ZTS) has given a return of -4.81% in the last 3 years.
Zoetis Inc Class A (ZTS) has a market capitalisation of $ 68,457 Mln as on 25-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/E ratio of Zoetis Inc Class A (ZTS) is 28.06 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Zoetis Inc Class A (ZTS) and enter the required number of quantities and click on buy to purchase the shares of Zoetis Inc Class A (ZTS).
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
The CEO & director of Ms. Kristin C. Peck. is Zoetis Inc Class A (ZTS), and CFO & Sr. VP is Ms. Kristin C. Peck.
There is no promoter pledging in Zoetis Inc Class A (ZTS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
74,481
|
|
|
38,015
|
|
|
31,320
|
|
|
19,872
|
| Zoetis Inc. Class A (ZTS) | Ratios |
|---|---|
|
Return on equity(%)
|
50.91
|
|
Operating margin(%)
|
36.28
|
|
Net Margin(%)
|
26.86
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of Zoetis Inc Class A (ZTS) was $2,486 Mln.
$0.48
(
